Our Platform

We are developing next generation in situ CAR T/NK cell therapies, which use nanobody CAR (nanoCAR) and tumor modulating element (Tmode™) circular RNAs and nanobody-targeted lipid nanoparticles (nLNP) to redefine the treatment of hematologic malignancies, solid tumors, and autoimmune diseases.

NanoCAR improves T/NK signaling stability and antigen specificity. Tmode™ modulates the tumor microenvironment, allowing effective CAR T/NK penetration and efficient tumor killing. A smaller size targeting nanobody maximizes the valency and minimizes the immunogenicity of nLNP.

Our Mission

We leverage, integrate, and apply the most advanced nanobody, circular RNA, and lipid nanoparticle technologies at the forefront of immunotherapy and cell therapy for the treatment of diseases with unmet medical needs.

About Us

We are a team of molecular cell engineers, application scientists, and fervent entrepreneurs who recognize the transformative potential of integrating nanobodies, circular RNAs, and lipid nanoparticles to create a novel class of RNA biologics for in situ therapeutic applications.

News & Events

Citil Pharma Presents CD8 nanobody-targeted lipid nanoparticles encapsulating CD13 nanoCAR circular RNAs for in situ CAR-T cell eradication of acute myeloid leukemia at the American Association for Cancer Research Annual Meeting 2026

Citil Pharma Presents CDH17 nanoCAR circular RNAs and CD11b nanobody-targeted lipid nanoparticles enable in situ CAR-NK/NKT cell generation for effective treatment of colorectal cancer at the American Society of Gene and Cell Therapy Annual Meeting 2026

Citil Pharma Presents In vivo programming of circulating T cells with membrane-anchored IL-12 circular RNA lipid nanoparticles enables safe and effective treatment of solid tumor metastasis in syngeneic mouse models at the Society for Immunotherapy of Cancer Annual Meeting 2026